国家药监局批准康方生物的依若奇单抗注射液上市,适用于中度至重度斑块状银屑病治疗。该药物是国内首个针对IL-12和IL-23p40全人源单克隆抗体,有望成为银屑病新疗法。全球仅有两款IL-12/IL-23抑制剂药物上市,其中之一即为康方生物的依若奇单抗。
Source Link国家药监局批准康方生物的依若奇单抗注射液上市,适用于中度至重度斑块状银屑病治疗。该药物是国内首个针对IL-12和IL-23p40全人源单克隆抗体,有望成为银屑病新疗法。全球仅有两款IL-12/IL-23抑制剂药物上市,其中之一即为康方生物的依若奇单抗。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.